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Dysregulated S-nitrosylation of proteins characterizes a broad array of human disorders, but its 
role in disease etiology is not well understood. Two new studies (Durham et al., 2008; Bellinger 
et al., 2008) now show that hyper-S-nitrosylation of the ryanodine receptor calcium release 
channel (RyR1) in skeletal muscle disrupts calcium ion flux. This disruption underlies the impaired 
contractility and cellular damage of skeletal muscle during strenuous exercise and in a spectrum 
of congenital muscle disorders including malignant hyperthermia.There has been a recent seachange 
in the way that redox systems biol-
ogy is viewed, with oxidative stress 
now being thought of not so much as 
a primary cause of disease but rather 
as a consequence of dysregulated 
signaling and impaired cellular func-
tion. This viewpoint has implications 
both for understanding the nature of 
redox events in signaling pathways and 
in pathophysiology, and for designing 
better therapeutics. In particular, the 
frequent failure in clinical trials of anti-
oxidants may be rationalized by their 
inability to address primary defects in 
redox-based signaling. Fatigue of skel-
etal muscle, which is strongly linked 
to oxidative stress (Reid et al., 1994), 
is a common cause of weakness (and 
muscle damage) in respiratory disease, 
heart failure, congenital muscle disor-
ders, and atrophic syndromes, includ-
ing cachexia (muscle wasting), cancer, 
and aging. One immediate question 
is the nature of the cellular signal dis-
rupted in fatigued skeletal muscle that 
results in oxidative stress. Answers to 
this question would shed light on the 
molecular basis of muscle injury and 
thus could suggest possible corrective 
measures.
Two recent papers—one by Durham 
et al. (2008) in this issue of Cell and 
another by Bellinger et al. (2008) in a 
recent issue of Proc. Natl. Acad. Sci. 
USA—now identify this cellular signal 
as nitric oxide (NO)-based. Viewed 
together, these studies suggest a con-
tinuum—from normal muscle contrac-tion to muscle fatigue and malignant 
hyperthermia (MH)—that reflects the 
extent of modification of the ryanodine 
receptor calcium release channel (RyR1) 
by S-nitrosylation, ultimately resulting 
in leaky channels. Furthermore, muta-
tions in RyR1 associated with MH (as 
well as a disorder called central core 
disease) are shown to increase the 
sensitivity of this calcium ion channel 
to NO, particularly at elevated tem-
peratures. This observation provides 
support for the idea that hyper-S-ni-
trosylation of mutant RyR1 underlies 
the exercise-induced contractures and 
life-threatening muscle injury of exer-
tional heat stroke (Durham et al., 2008; 
Wappler et al., 2001). Sustained eleva-
tion of cytosolic calcium ions can raise 
respiratory activity of mitochondria 
and enhance their production of oxi-
dants. Mitochondrial oxidative stress 
may therefore explain the injury to 
this organelle (swelling and formation 
of central cores) that may accompany 
congenital muscle disorders caused by 
RyR1 mutations, including MH, exer-
tional heat stroke, and central core 
disease (Durham et al., 2008). Collec-
tively, these results suggest a common 
molecular basis for muscle disorders 
associated with dysregulated handling 
of calcium ions by RyR1, and may her-
ald a new era for developing therapeu-
tic approaches for treating oxidative 
and nitrosative stress.
In skeletal muscle, a splice variant 
of the neuronal isoform of nitric oxide 
synthase (nNOS) associates with the Csarcolemmal dystrophin complex, and 
also localizes to the cytosol where 
(at least in heart muscle) it coimmu-
noprecipitates with the RyR channel 
(Kobzik et al., 1994; Gonzalez et al., 
2007). Although two other isoforms of 
NOS may be constitutively expressed 
in muscle and upregulated by exercise, 
nNOS is most clearly identified with 
contractile function. Notably, activity 
of skeletal muscle is coupled to nNOS 
expression, and mislocalization of 
nNOS occurs in muscular dystrophies, 
cachexia/atrophic syndromes, and 
heart failure. The two new studies sug-
gest that RyR1 is a source of the cal-
cium ions that activate nNOS (Durham 
et al., 2008) and that calcium-depen-
dent upregulation of nNOS activity by 
either sustained exercise or RyR muta-
tions leads to hyper-S-nitrosylation of 
RyR1 in mice and humans (Durham et 
al., 2008; Bellinger et al., 2008).
Oxygen tension (pO2) is low in resting 
muscle (?20 mm Hg) and falls with mild 
exercise. At physiological pO2, but not 
in room air, endogenous NO appears 
to activate RyR1 by S-nitrosylating one 
cysteine residue among ?50 free thi-
ols in each RyR subunit (Figure 1). This 
cysteine (C3635) resides in a hydro-
phobic compartment within the calm-
odulin-binding domain of RyR1 (Eu et 
al., 2000; Sun et al., 2003). Physiologi-
cal activation of RyR1 by NO involves 
perturbation of a complex between 
calmodulin and RyR1. The require-
ment for physiological pO2 entails an 
allosteric effect of a small set (six to ell 133, April 4, 2008 ©2008 Elsevier Inc. 33
eight) of additional RyR thiols whose 
redox state governs S-nitrosylation by 
NO. These pO2-responsive RyR thiols 
undergo oxidation in room air (prob-
ably by hydrogen peroxide generated 
by mitochondria or endogenous oxi-
dases). Thus, under normal conditions, 
contractility of skeletal muscle reflects 
the precise regulation of S-nitrosyla-
tion (and its effects) by tissue pO2 and 
calmodulin.
Another set of RyR thiols may serve 
as a redox sensor by coupling calcium-
ion release to the ratio of cellular glu-
tathione (GSH) to glutathione disulfide 
(GSSG). An additional set of RyR thiols 
may confer responsiveness to S-ni-
trosoglutathione (GSNO) (Sun et al., 
2003; Aracena-Parks et al., 2006 and 
references therein). GSSG and GSNO 
activate the RyR channel by S-glutathi-
onylation and S-nitrosylation, respec-
tively. Unlike NO and GSSG, GSNO 
can inhibit the interaction of the protein 
FKBP12 with RyR1 (Bellinger et al., 2008 
and references therein); displacement 
of FKBP12 destabilizes the channel, 
which becomes leaky. Thus, hydrogen 
peroxide, GSNO, and GSSG activate 
RyR1 through different cysteine-based 
modifications of different sets of thiols. 
The physiological or pathophysiologi-
cal roles of these modifications have 
remained unclear.
Durham and colleagues studied mice 
carrying a mutation in RyR that causes 
MH in humans. They demonstrate 
that skeletal muscle from these mice 
exhibits hallmarks of both oxidative 
stress (decreased GSH/GSSG ratio, 
and increased S-glutathionylation of 
RyR) and nitrosative stress (increased 
S-nitrosylation of RyR). These results 
are reminiscent of dysregulated S-ni-
trosylation of RyR in cardiac muscle, 
which also leads to leaky channels 
and oxidative stress (Gonzalez et al., 
2007). Significantly, inhibition of NOS 
in the mutant mouse muscle restored 
the cellular GSH/GSSG balance, indi-
cating that nitrosative stress mediates 
oxidative stress (Durham et al., 2008). 
Because the amounts of NO derived 
from nNOS are much lower than cel-
lular glutathione, increased nNOS 
activity presumably inhibits enzymes 
involved in glutathione synthesis or 
reduction. Treatment of mutant mice 
Figure 1. Nitrosative Stress and Muscle Injury
(A–C) Each subunit of the tetrameric ryanodine receptor calcium release channel (RyR1) within the sar-
coplasmic reticulum of skeletal muscle possesses several discrete sets of cysteine thiols. These thiols 
are defined by differential susceptibility to modification by different endogenous redox active molecules: 
nitric oxide (NO), S-nitrosoglutathione (GSNO), glutathione disulfide (GSSG), and reactive oxygen species 
(ROS) such as hydrogen peroxide. The amounts and sources of these reactive molecules differ in rest-
ing muscle, after exercise, and with muscle injury. In (A), under normal conditions, neuronal nitric oxide 
synthase (nNOS) activates the RyR1 channel by S-nitrosylating up to one cysteine residue (Cys3635) per 
RyR subunit (four cysteines per RyR1 channel). S-nitrosylation (NO, light red) is coupled to muscle activ-
ity during moderate exercise through both increases in nNOS activity (increased cytosolic calcium ions) 
and a decline in tissue pO2 that entails allosteric regulation of the RyR. In (B), with sustained exercise or 
in the presence of RyR mutations (e.g., in the disease malignant hyperthermia), increased calcium-ion 
release promotes aberrant S-nitrosylation (NO, dark red), which in turn results in dysregulated calcium 
ion flux. This feed-forward cycle is marked by hyper-S-nitrosylation of the RyR channel and leakage of 
calcium ions. Hyper-S-nitrosylation increases the temperature sensitivity of mutant RyR1 to activation 
and thus provides a molecular basis for the clinical syndromes of malignant hyperthermia and exertional 
heat stroke. In (C), nitrosative stress predisposes to oxidative stress. Formation of GSSG promotes S-
glutathionylation (S-SG) of the RyR channel, which may accentuate leakage of calcium ions. Ultimately, 
mitochondria become activated (perhaps by a sustained elevation of calcium-ion levels), which increases 
their oxidative burden and the production of ROS, resulting in mitochondrial damage and its ramifications 
(e.g., central core disease). Further S-oxidation of RyR (S-Ox) is an inevitable consequence of mitochon-
drial and cellular injury. Thus, normal contractility, exercise, fatigue, malignant hyperthermia, exertional 
heat stroke, and central core disease may be viewed as a continuum from physiological S-nitrosylation 
to hyper-S-nitrosylation (nitrosative stress) and ultimately to oxidative injury of muscle.34 Cell 133, April 4, 2008 ©2008 Elsevier Inc.
with the thiol N-acetylcysteine (NAC), 
which restores the GSH/GSSG bal-
ance, lowered S-glutathionylation 
and S-nitrosylation of mutant RyR, 
but had no affect on basal S-nitrosy-
lation. These data point to an equilib-
rium between S-nitrosylated RyR and 
GSNO that is disrupted during nitrosa-
tive stress, as well as to the seques-
tration of basal S-nitrosylated RyR in 
a solvent-inaccessible compartment 
characteristic of S-nitrosylated C3635 
(Figure 1). Although quantification and 
mapping of RyR S-nitrosylation will be 
needed to elucidate hyper-S-nitrosyla-
tion, strikingly, selective removal of the 
S-nitroso group by ascorbate normal-
ized the temperature sensitivity of RyR 
from mice with the MH mutation.
A GSNO reductase (GSNOR) metab-
olizes GSNO thereby promoting de-S-
nitrosylation of proteins by glutathione 
(Figure 1). In contrast, solvent inac-
cessible S-nitrosylated proteins are 
subject to denitrosylation by as yet 
unidentified enzymes and are charac-
teristically unresponsive to the acute 
effects of NOS inhibitors, as observed 
for RyR1 (Durham et al., 2008). These 
results emphasize that aberrant S-ni-
trosylation of RyR1 may reflect dysreg-
ulated removal of NO groups.
Bellinger et al. (2008) extend these 
observations into the physiologi-
cal realm of exercise. They show that 
strenuous exercise in mice and humans 
is associated with gradual hyper-S-ni-
trosylation of RyR1 that is accompanied 
by depletion of FKBP12, resulting in 
leaky channels that impair exercise tol-
erance. Thus, there is overlap between 
the molecular signatures of extreme 
fatigue and of MH/exertional heat 
stroke. Selective de-S-nitrosylation of 
RyR channels, as reported by Durham 
et al. (2008), may provide a mecha-
nism for improving exercise capacity. 
Bellinger et al. (2008) also observed that muscle fatigue is accompanied by 
hyperphosphorylation of RyR1 medi-
ated by protein kinase A (PKA), which 
results in displacement of FKBP12. 
Inhibitors of PKA-mediated phospho-
rylation may therefore protect against 
MH and exertional heat stroke. The 
effect of phosphorylation on the affin-
ity of FKBP12 for RyR has been con-
troversial. The new data now suggest 
that there may be allosteric coupling 
between S-nitrosylation and phospho-
rylation. Further attention to the redox 
state of RyR may help to resolve the 
controversy.
This new work suggests fresh ther-
apeutic opportunities. Durham and 
coworkers show that NAC reverses 
hyper-S-nitrosylation of RyR chan-
nels and leakage of calcium ions in 
vitro, and that treatment for several 
months improves force generation in 
muscle and reverses mitochondrial 
injury in mice with the MH mutation. 
However, correction by NAC of the 
S-nitrosylation signaling defect in skel-
etal muscle may be counterbalanced 
by creation of another: conversion of 
NAC to S- nitroso-NAC in vivo depletes 
red blood cell S-nitrosohemoglobin 
and causes pulmonary hypertension 
(Palmer et al., 2007). Perhaps the tox-
icity of chronic NAC therapy can be 
averted at lower doses or its effects 
replicated by muscle-specific alterna-
tives. Inhibitors of nNOS, which prevent 
hyper-S-nitrosylation of RyR (Durham 
et al., 2008), may also be useful in some 
instances. Bellinger and colleagues 
offer a complementary approach: a 
small molecule that stabilizes the inter-
action of FKBP12 with the hyper-S-
nitrosylated (or hyperphosphorylated) 
RyR channel, probably by stabilizing 
a channel conformation that favors 
binding of FKBP12. Remarkably, this 
molecule improved force generation 
and protected against muscle injury. A Cegrowing list of disorders are character-
ized by dysregulated S-nitrosylation, 
including Parkinson’s disease, atrial 
fibrillation, sickle cell disease, pulmo-
nary hypertension, cystic fibrosis, can-
cer, and heart failure. The new findings 
in skeletal muscle suggest that agents 
that modulate S-nitrosylation or its 
effects may represent a new class of 
therapeutics that could be of benefit in 
treating a broad spectrum of diseases.
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